INCRUSE ELLIPTA Market Summary

Key Factors Driving INCRUSE ELLIPTA Growth

1. Strong positioning as a once-daily LAMA therapy

INCRUSE ELLIPTA’s once-daily dosing and simple ELLIPTA dry-powder inhaler design remain important commercial drivers. COPD patients often require long-term maintenance therapy, and adherence improves with simplified dosing regimens. Clinical studies conducted by GSK showed INCRUSE delivered superior bronchodilation versus tiotropium and glycopyrronium in several lung-function endpoints, strengthening physician confidence in the product.

2. Large and growing global COPD burden

COPD continues to represent a major long-term respiratory market opportunity. GSK cited estimates from the National Heart, Lung, and Blood Institute showing nearly 27 million people in the U.S. alone are affected by COPD. Globally, aging populations, smoking exposure, biomass fuel exposure, and worsening air pollution continue to expand the COPD treatment population, particularly in emerging markets. Chronic maintenance therapy requirements support durable demand for bronchodilators such as INCRUSE ELLIPTA.

3. Growth driven by the broader ELLIPTA respiratory franchise

INCRUSE benefits strategically from GSK’s broader ELLIPTA respiratory ecosystem, which includes blockbuster products such as TRELEGY ELLIPTA, BREO/RELVAR ELLIPTA, and ANORO ELLIPTA. Physician familiarity with the ELLIPTA inhaler platform improves prescribing comfort and supports cross-franchise adoption. GSK’s respiratory portfolio continues to show strong growth momentum, with Respiratory/Immunology sales rising 13% in FY2024 and 18% in FY2025.

4. Historical rapid commercial uptake validates market acceptance

During its early commercialization phase, INCRUSE demonstrated rapid uptake within the COPD bronchodilator segment. GSK’s quarterly reports previously showed INCRUSE sales growth exceeding 50-60% year over year in several reporting periods after launch, validating physician acceptance of umeclidinium as a competitive LAMA option. The product’s continued inclusion in respiratory maintenance regimens has helped sustain relevance despite increasing generic and branded competition.

5. Broad international approvals and geographic expansion

INCRUSE ELLIPTA has received approvals across major global markets including the U.S., European Union, Canada, and Australia. GSK highlighted that the EU approval covered all member states and was supported by a Phase III program involving more than 2,500 COPD patients. Broader geographic availability supports long-term prescription volume growth, especially in regions with rising COPD prevalence.

6. Potential durability through combination therapy strategies

Although monotherapy competition has intensified, umeclidinium remains strategically important within GSK’s combination respiratory portfolio. The success of combination inhalers using ELLIPTA technology, particularly triple therapy TRELEGY ELLIPTA, reinforces the long-term value of the umeclidinium franchise. GSK reported TRELEGY sales reached approximately £3.0 billion in 2025, highlighting continued physician demand for ELLIPTA-based COPD regimens and indirectly supporting ongoing utilization of INCRUSE-containing therapeutic strategies.

INCRUSE ELLIPTA Recent Developments

In April 2024, European Commission granted marketing authorization April 2014 for 55mcg once-daily inhalation powder; first launches in Europe by end of 2014; licensed across all 27 EU member states.

“INCRUSE ELLIPTA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of INCRUSE ELLIPTA for approved indication like Chronic obstructive pulmonary disease; as well as potential indication like Hyperhidrosis in the 7MM. A detailed picture of INCRUSE ELLIPTA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the INCRUSE ELLIPTA for approved and potential indications. The INCRUSE ELLIPTA market report provides insights about INCRUSE ELLIPTA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current INCRUSE ELLIPTA performance, future market assessments inclusive of the INCRUSE ELLIPTA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of INCRUSE ELLIPTA sales forecasts, along with factors driving its market.

INCRUSE ELLIPTA Drug Summary

INCRUSE ELLIPTA is a once-daily long-acting muscarinic antagonist (LAMA) developed by GSK for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The drug contains umeclidinium bromide and is administered through the ELLIPTA dry powder inhaler device, providing sustained bronchodilation by selectively blocking muscarinic M3 receptors in airway smooth muscle. INCRUSE ELLIPTA is designed to improve lung function, reduce airflow limitation, and alleviate symptoms such as breathlessness in COPD patients. Clinical trials have demonstrated significant improvements in forced expiratory volume (FEV1), symptom control, and convenience through its once-daily dosing regimen and user-friendly inhaler platform, making it a widely used maintenance bronchodilator either as monotherapy or in combination regimens for COPD management. The report provides INCRUSE ELLIPTA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the INCRUSE ELLIPTA Market Report

The report provides insights into:

• A comprehensive product overview including the INCRUSE ELLIPTA MoA, description, dosage and administration, research and development activities in approved indications like Chronic obstructive pulmonary disease; as well as potential indication like Hyperhidrosis.
• Elaborated details on INCRUSE ELLIPTA regulatory milestones and other development activities have been provided in INCRUSE ELLIPTA market report.
• The report also highlights INCRUSE ELLIPTA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The INCRUSE ELLIPTA market report also covers the patents information, generic entry and impact on cost cut.
• The INCRUSE ELLIPTA market report contains current and forecasted INCRUSE ELLIPTA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The INCRUSE ELLIPTA market report also features the SWOT analysis with analyst views for INCRUSE ELLIPTA in approved and potential indications.

Methodology

The INCRUSE ELLIPTA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INCRUSE ELLIPTA Analytical Perspective by DelveInsight

• In-depth INCRUSE ELLIPTA Market Assessment

This INCRUSE ELLIPTA sales market forecast report provides a detailed market assessment of INCRUSE ELLIPTA for approved indication like Chronic obstructive pulmonary disease; as well as potential indication like Hyperhidrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted INCRUSE ELLIPTA sales data uptil 2034.

• INCRUSE ELLIPTA Clinical Assessment

The INCRUSE ELLIPTA market report provides the clinical trials information of INCRUSE ELLIPTA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

INCRUSE ELLIPTA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

INCRUSE ELLIPTA Market Potential & Revenue Forecast

• Projected market size for the INCRUSE ELLIPTA and its key indications
• Estimated INCRUSE ELLIPTA sales potential (INCRUSE ELLIPTA peak sales forecasts)
• INCRUSE ELLIPTA Pricing strategies and reimbursement landscape

INCRUSE ELLIPTA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• INCRUSE ELLIPTA Market positioning compared to existing treatments
• INCRUSE ELLIPTA Strengths & weaknesses relative to competitors

INCRUSE ELLIPTA Regulatory & Commercial Milestones

• INCRUSE ELLIPTA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

INCRUSE ELLIPTA Clinical Differentiation

• INCRUSE ELLIPTA Efficacy & safety advantages over existing drugs
• INCRUSE ELLIPTA Unique selling points

INCRUSE ELLIPTA Market Report Highlights

• In the coming years, the INCRUSE ELLIPTA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The INCRUSE ELLIPTA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INCRUSE ELLIPTA’s dominance.
• Other emerging products for Chronic obstructive pulmonary disease; as well as potential indication like Hyperhidrosis are expected to give tough market competition to INCRUSE ELLIPTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INCRUSE ELLIPTA in approved and potential indications.
• Analyse INCRUSE ELLIPTA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted INCRUSE ELLIPTA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of INCRUSE ELLIPTA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of INCRUSE ELLIPTA? How strong is INCRUSE ELLIPTA’s clinical and commercial performance?
• What is INCRUSE ELLIPTA’s clinical trial status in each individual indications such as Chronic obstructive pulmonary disease; as well as potential indication like Hyperhidrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INCRUSE ELLIPTA Manufacturers?
• What are the key designations that have been granted to INCRUSE ELLIPTA for approved and potential indications? How are they going to impact INCRUSE ELLIPTA’s penetration in various geographies?
• What is the current and forecasted INCRUSE ELLIPTA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of INCRUSE ELLIPTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to INCRUSE ELLIPTA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is INCRUSE ELLIPTA? What is the duration of therapy and what are the geographical variations in cost per patient?